Related Experiment Video
Updated: Mar 7, 2026
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
The polypill approach - An innovative strategy to improve cardiovascular health in Europe
Valentín Fuster1,2, Francesc Gambús3, Aldo Patriciello4
1Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain.
Insights
Cardiovascular disease (CVD) management is improved by polypills, which enhance medication adherence and prevent recurrent cardiovascular events. This innovative approach offers a cost-effective strategy for improving cardiovascular health outcomes.
Area of Science:
- Cardiology
- Public Health
- Pharmacology
Background:
- Cardiovascular disease (CVD) remains a leading cause of premature death and disability.
- Many patients with CVD do not adhere to guideline-recommended medical therapies, necessitating innovative solutions.
- European health authorities and cardiology societies recognize the need for improved cardiovascular health strategies.
Purpose of the Study:
- To evaluate the effectiveness of polypills in improving medication adherence for cardiovascular disease (CVD) prevention.
- To assess the impact of polypills on preventing fatal and non-fatal cardiovascular events.
- To determine the cost-effectiveness of polypills in managing CVD and supporting healthcare sustainability.
Main Methods:
- Investigated polypills as a strategy to improve treatment adherence in cardiovascular disease (CVD).
- Reviewed numerous studies demonstrating the efficacy of polypills in enhancing medication adherence.
- Considered the recent availability of the first cardiovascular polypill in Europe for general prescription.
Main Results:
- Polypills significantly improve medication adherence in patients with cardiovascular disease (CVD).
- Improved adherence through polypills contributes to better health outcomes and prevention of cardiovascular events.
- The cardiovascular polypill is a cost-effective strategy for improving healthcare system sustainability in CVD management.
Conclusions:
- The polypill approach offers an urgent and simple solution to the high prevalence of cardiovascular disease (CVD).
- Physicians and public health systems should consider polypills as an innovative option for improving cardiovascular health.
- Polypills represent a significant advancement in managing CVD and promoting long-term patient well-being.
Background:
Cardiovascular disease (CVD) is a major cause of disability and premature death. Despite European guidelines advocating the use of medical therapies in CVD, many patients still do not achieve the guideline-recommended treatment, which highlights the need for change and innovations in this field. This requirement has been widely recognised by the national ministries of health, several European cardiology societies, and the European Parliament, who support the initiation of strategies to improve and promote cardiovascular health.
Discussion:
One of the key risk factors to recurrent cardiovascular events is the lack of adherence to medication and this has been added to the agenda of the European Commission. With the intention to improve treatment adherence in CVD, polypills have been investigated and numerous studies demonstrate that they significantly improve medication adherence, which contributes to the improvement of health outcomes. In Europe, the first cardiovascular polypill, developed by a public-private partnership (CNIC-Ferrer), recently became available for general prescription as a therapy for CVD prevention. This polypill significantly improves adherence, preventing fatal and non-fatal cardiovascular events, and appears to be a cost-effective strategy to improve sustainability of the health care systems in CVD.
Conclusions:
Given the importance of urgent and simple solutions to restraining the pandemic nature of CVD, the polypill approach should therefore be considered by physicians and public health systems as an available and innovative option to improve cardiovascular health.
Related Concept Videos
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:23Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...